To Develop Japan’s First Blood Biomarker-Based Diagnostic Workflow for Dementia Shimadzu, Eisai, Oita University, and Usuki City Medical Association Commence Joint Research

TOKYO, Nov 22, 2022 – (JCN Newswire via SEAPRWire.com) – Shimadzu Corporation (Shimadzu), Eisai Co., Ltd. (Eisai), Oita University, and Usuki City Medical Association hereby announce the commencement of a cohort study using Usuki City as a demonstration site. This joint study will attempt to develop Japan’s first diagnostic workflow for mild cognitive impairment (MCI) […]

Hua Medicine’s Innovative First-In-Class Glucokinase Activator (GKA) HuaTangNing Is Approved, New Type 2 Diabetes Treatment Paradigm to Begin in China

SHANGHAI, CHINA, Oct 10, 2022 – (ACN Newswire via SEAPRWire.com) – Hua Medicine (the “Company”, HKEx Stock Code: 2552.HK) today announces that the New Drug Application (NDA) of HuaTangNing (dorzagliatin tablets, HMS5552), a first-in-class glucokinase activator (GKA) developed by the Company has been approved by the National Medical Products Administration (NMPA) of China on October […]

Cryoviva Singapore Gets AABB Accreditation for Somatic Cells’ Processing, Storage, and Distribution

Singapore, Nov 2, 2021 – (ACN Newswire via SEAPRWire.com) – Family cord blood bank Cryoviva Singapore is pleased to announce that it has now been accredited by the Association of the Advancement of Blood & Biotherapies (AABB), formerly known as the American Association of Blood Banks, for both cord blood and somatic cells’ banking services. […]

Cryoviva Singapore Expands Cord Blood Banking Services to Bahrain

Singapore, Sep 7, 2021 – (ACN Newswire via SEAPRWire.com) – Local family cord blood bank Cryoviva Singapore (https://cryoviva.com.sg) is continuing with its rapid geographic growth plans with an entry into the Bahrain market. This latest new market entry closely follows Cryoviva establishing a footprint in Dubai to serve couples in the UAE that are on […]